12,372 trials
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS) — 16.59; 19.35…
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival (PFS) as Determined by the Investigator — 9.89; 8.31 months — p=0.9912
Chronic Obstructive Pulmonary Disease (COPD)
Primary: 1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26 — 0.082; 0.001 litre — p=< 0.001
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.23 Percentage (%) of HbA1c — p=<0.0001
Locally Advanced or Metastatic Unresectable Urothelial Cancer
Primary: Overall Survival (OS) — 10.3; 9.0 months — p=0.0870
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 5; 11 Participants
Hereditary Angioedema
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 146 Participants
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage Change From Baseline in LDH at Week 12 — -76.5 percentage change — p=<0.001
Chronic Kidney Disease 5D
Primary: High-sensitivity C-reactive Protein — 11.16; 11.84 milligrams per liter (mg/L) — p=0.004
Asthma
Primary: 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 — 0.229; 0.157; 0.274 Liter — p=0.003
Healthy Volunteers
Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years…
Glabellar Frown Lines · Canthal Lines
Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
Dermatitis, Contact
Primary: Number of Participants Who Develop Contact Dermatitis — 21; 18 Participants
COVID19 · Coronavirus Infection · Coronavirus
Primary: Time of Meeting Infusion Criteria to Infusion — 1 days
SARS-CoV-2 Infection, COVID-19
Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age — 12.5; 0; 100.0; 16.7 Percentage of participants